Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A22-102
Last updated

Report documents

  1. Extract of dossier assessment

    Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 879 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 879 kB, EN, not accessible)

  2. Dossier assessment

    Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Dossier assessment

Indication:

adjuvant treatment of adult patients with HER2-positive, early breast cancer at high risk of recurrence (node-positive or hormone receptor-negative)

Result of dossier assessment:

indication of minor added benefit

Press releases

Pertuzumab and pertuzumab/trastuzumab in breast cancer: now minor added benefit

Advantages in overall survival and recurrence often only become apparent after a longer period of time – current early benefit assessment proves how useful it is to limit the validity of the resolution on a benefit assessment in certain therapeutic indications.
Press release

Project details

Project no.
A22-102
Commission
Commission awarded on 29.09.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Pertuzumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

    Project no.
    A13-10
    Last updated

    Status: Commission completed

  2. Addendum

    Addendum to Commission A13-10 (pertuzumab)

    Project no.
    A13-28
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)

    Project no.
    A15-34
    Last updated

    Status: Commission completed

  4. Addendum

    Pertuzumab - Addendum to Commission A15-34

    Project no.
    A16-01
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-41
    Last updated

    Status: Commission completed

  6. Addendum

    Pertuzumab (breast cancer) - Addendum to Commission A18-41

    Project no.
    A18-76
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page